

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 06275-0492US1	Application No. 10/566,054
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Ambrose et al.		
		Filing Date June 27, 2006	Group Art Unit 1637	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	4,376,110	03/08/83	David et al.			
	2	4,411,993	10/25/83	Gillis			
	3	4,486,530	12/04/84	David et al.			
	4	4,543,439	09/24/85	Frackleton, Jr. et al.			
	5	4,902,614	02/20/90	Wakabayashi et al.			
	6	5,210,015	05/11/93	Gelfand et al.			
	7	5,487,972	01/30/96	Gelfand et al.			
	8	RE 32,011	10/22/85	Zimmerman et al.			

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
							Yes No
	9	WO 95/13399	05/18/95	WO			
	10	WO 00/08157	02/17/00	WO			
	11	0 332 435	04/22/92	EP			
	12	1 186 672	11/30/05	EP			
	13	2 228 998	09/12/90	GB			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	14	EMBL Accession No. AB026257 dated July 29, 2000
	15	EMBL Accession No. AC022335 dated October 31, 2002
	16	EMBL Accession No. AF205071 dated December 28, 1999
	17	EMBL Accession No. AJ132573 dated October 7, 2008
	18	EMBL Accession No. AF060500 dated June 15, 1999
	19	Alting-Mees et al., "Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas," <i>Strategies in Molecular Biology</i> , 1990, 3:1-9
	20	Brown, "Rosuvastatin is a High Affinity Substrate of Hepatic Organic Anion Transporter OATP-C," <i>Atherosclerosis Supplements</i> 2, 2001, page 90, Abstract P174
	21	Chong and Seeger, "Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors," <i>Pharmacotherapy</i> , 1997, 17(6):1157-1177

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 06275-0492US1	Application No. 10/566,054
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Ambrose et al.	
		Filing Date June 27, 2006	Group Art Unit 1637

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	22	Dujovne, "New lipid lowering drugs and new effects of old drugs," <u>Current Opinion in Lipidology</u> , 1997, 8:362-368
	23	Forbes (ed.), "HMG-CoA reductase inhibitors: a first-line option," <u>Drugs and Therapy Perspectives</u> , 1997, 9:1-6
	24	Gibbs et al., "Detection of Single DNA Base Differences by Competitive Oligonucleotide Priming," <u>Nucl. Acids Res.</u> , 1989, 17(7):2437-2448
	25	Hsiang et al., "A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters," <u>J. Biol. Chem.</u> , 1999, 274(52):37161-37168
	26	Igel et al., "Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin," <u>J. Clin. Pharmacol.</u> , 2002, 42:835-845
	27	Jahng, "Design of a new class of HMG-CoA reductase inhibitors," <u>Drugs of the Future</u> , 1995, 20:387-404
	28	Jung et al., "Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1 alpha," <u>J. Biol. Chem.</u> , 2001, 276(40):37206-37214
	29	Kathawala, "HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia," <u>Med. Res. Rev.</u> , 1991, 11:121-146
	30	Kellick et al., "Focus on atorvastatin: An HMG-CoA reductase inhibitor for Tx of hypercholesterolemia," <u>Formulary</u> , 1997, 32:352
	31	König et al., "Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide," <u>J. Biol. Chem.</u> , 2000, 275(30):23161-23168
	32	Larrick et al., "Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes From Single Hybridoma Cells," <u>Biotechnology</u> , 1989, 7:934-
	33	Niemi et al., "High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLC01B1)," <u>Pharmacogenetics</u> , 2004, 14(7):429-440
	34	Nishizato et al., "Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics," <u>Clin. Pharmacol. Ther.</u> , 2003, 73:554-565
	35	Nollau and Wagener, "Methods for detection of point mutations: performance and quality assessment," <u>Clin. Chem.</u> , 1997, 43:1114-1128
	36	Nozawa et al., "Genetic Polymorphisms of Human Organic Anion Transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): Allele Frequencies in the Japanese Population and Functional Analysis," <u>J. Pharmacol. Exp. Ther.</u> , 2002, 302:804-813
	37	Olsson, "Statin Therapy and Reductions in Low-Density Lipoprotein Cholesterol: Initial Clinical Data on the Potent New Statin Rosuvastatin," <u>Am. J. Cardiol.</u> , 2001, 87(suppl):33B-36B
	38	Park et al., "Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporine A," <u>Int. J. Clin. Pharmacol Ther.</u> , 2002, 40:439-450
	39	Rowland and Tozer (eds.), "Disease," <u>Clinical Pharmacokinetics</u> , 1995, 3 rd edition, Chapter 16, pps. 248-266, Williams & Wilkins
	40	Scatchard, "The Attractions of Proteins for Small Molecules and Ions," <u>Ann. N.Y. Acad. Sci.</u> , 1949, 51:660-672

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 06275-0492US1	Application No. 10/566,054
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Ambrose et al.	
		Filing Date June 27, 2006	Group Art Unit 1637

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	41	Stephens et al., "A New Statistical Method for Haplotype Reconstruction from Population Data," <u>Am. J. Human Genet.</u> , 2001, 68:978-989
	42	Tamai et al., "Molecular Identification and Characterization of Novel Members of the Human Organic Anion Transporter (OATP) Family," <u>Biochem. Biophys. Res. Comm.</u> , 2000, 273:251-260
	43	Tirona and Kim, "Pharmacogenomics of organic anion-transporting polypeptides (OATP)," <u>Adv. Drug Del. Rev.</u> , 2002, 54:1343-1352
	44	Tyagi and Kramer, "Molecular Beacons: Probes that Fluoresce Upon Hybridization," <u>Nat. Biotechnol.</u> , 1996, 14:303-308
	45	Watanabe et al., "Synthesis and Biological Activity of Methanesulfonamide Pyrimidine- and N-Methanesulfonyl Pyrrole-Substituted 3,5-Dihydroxy-6-heptenoates, a Novel Series of HMG-CoA Reductase Inhibitors," <u>Bioorg. Med. Chem.</u> , 1997, 5:437-444

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	